Navigation Links
Oncolytics Biotech(R) Inc. Announces 2009 Second Quarter Results
Date:7/29/2009

CALGARY, July 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ONCY) ("Oncolytics" or the "Company") today announced its financial results for the three and six-month periods ended June 30, 2009.

"Clinical results from our monotherapy and combination clinical trials with REOLYSIN(R) continued to emerge in the second quarter," said Dr. Brad Thompson, President and CEO of Oncolytics. "The results of these trials, and the response and clinical benefit rates as reported by our investigators, reinforce our belief that REOLYSIN has the potential to significantly improve treatment outcomes in patients with a broad range of cancers."

Selected Second Quarter Highlights

    -   Presented updated U.S. Phase II sarcoma trial data at the American
        Society of Clinical Oncology (ASCO) annual meeting. The interim
        results demonstrated that the treatment was well tolerated, with 15
        of 36, or 42% of evaluable patients experiencing stable disease (SD)
        for more than 16 weeks, including five patients who had SD for more
        than 24 weeks. Patient enrolment was completed in May;

    -   Presented a poster at ASCO demonstrating that the combination of
        REOLYSIN and gemcitabine in a U.K. Phase I trial was well tolerated,
        and resulted in disease control for a majority of the patients. Of
        the ten patients evaluable for response, two patients (breast and
        nasopharyngeal) had partial responses (PRs) and/or clinical responses
        and five patients had SD for 4-8 cycles, for a total disease control
        rate (CR (Complete Response)+PR+SD) of 70%;

    -   Presented a poster at ASCO that indicated REOLYSIN was well tolerated
        and demonstrated anti-tumour activity in a U.S. Phase I systemic
        administration monotherapy trial. Of 18
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, ... extension for the public comment period (Docket No. FAA-2014-0396) ... Aircraft established by Congress as part of the FAA ... establishes the new deadline for comments as September 23, ... notice published in the Federal Register on July 25, ...
(Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
(Date:7/24/2014)... computers have yet to materialise. Yet, scientists are ... such computers faster. One such approach relies on ... by applying an electric field. A new study ... coupled quantum dots (TQDs) with electrical impulses can ... example, should TQDs be used as quantum information ...
(Date:7/24/2014)... July 24, 2014 Your cell ... in modeling lithium-ion battery storage capacity. , New ... a theoretical model created at Lawrence Livermore ... that predicts how carbon components will perform as ... emphasizes the urgent need for higher-performance batteries. Several ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Getting More Life out of Lithium-ion Batteries 2
... Spanish . , Scientists at the University ... time different antioxidant compounds from foods such as olive oil, ... have used two new techniques, capillary electrophoresis and high resolution ... a great part of the phenolic compounds contained in these ...
... Dec. 8 Transgenomic, Inc. (OTC Bulletin Board: TBIO) announced ... first in a family of mutation detection kits the company ... ® HS DHPLC platform. SURVEYOR Scan technology is ... amplification reaction and hybridization to form heteroduplex DNA molecules in ...
... Dec. 8 PharmAthene, Inc. (NYSE Amex: PIP ) ... medical countermeasures against chemical and biological threats, announced today that ... Time, on Wednesday, December 9, 2009 to provide an update ... The dial-in number for U.S. callers is 866-383-8108 and for ...
Cached Biology Technology:New antioxidant compounds have been identified in foods such as olive oil, honey and nuts 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 2Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 3Transgenomic Announces the Commercial Launch of SURVEYOR(R) Scan K-RAS Mutation Detection Kit 4PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision 2
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
(Date:7/24/2014)... loss leads to conflict among people around the world, ... (WCS) Health & Ecosystems: Analysis of Linkages (HEAL) Program ... to tackle global biodiversity decline. , The harvest of ... people and provides protein for more than a billion ... surprise that today,s unprecedented loss of wildlife, is bringing ...
(Date:7/24/2014)... use of native animal species for food or commercial ... significant factor in the decline of many species of ... indicates that more than half of the species being ... hornbills., "By surveying not only the meat made available ... inside the forest by hunters and brought to villages ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3New study draws links between wildlife loss and social conflicts 2
... 2013 As an expert in molecular genetics, Colin E. ... Medical Center,s Institute for Regenerative Medicine is to apply the ... human organs. But, with a background specifically in reproductive ... the over-population of homeless dogs and cats. Bishop has been ...
... provides the same quality of fuel for athletes as a ... nutrients that are more commonly found in animal products, according ... (IFT) Annual Meeting & Expo. The research was compiled ... He was unable to attend the meeting, so his presentation ...
... Health has awarded Virginia Commonwealth University a grant totaling ... work which may one day point researchers to ... inflammatory conditions such as rheumatoid arthritis, multiple sclerosis and ... by John Ryan, Ph.D., associate professor in the Department ...
Cached Biology News:Low-cost sterilization method for cats and dogs is focus of new research project 2Monitoring nutrient intake can help vegetarian athletes stay competitive 2VCU receives NIH grant to examine the biology of allergic disease 2
Tris-Hepes kit of BG-163 & BG-165 (order number BG-166)...
... ideal for both radioactive and nonradioactive labeling ... Provides five pre-mixed nucleotide solutions for flexibility ... 8 cpm/g control DNA using [-32P]-dCTP ... performance of the system Labels 1 ...
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
... Immunogen: Fusion protein derived from ... ASIP/PAR-3 (atypical PKC isotype-specific interacting protein/ ... not related to the protease-activated-receptors also ... Xenopus (positive controls: Caco-2 MDCK A6 ...
Biology Products: